Eisai Inc.
Clinical trials sponsored by Eisai Inc., explained in plain language.
-
New Alzheimer's drug shows promise in slowing memory loss
Disease control CompletedThis study tested whether an investigational drug called lecanemab (BAN2401) could slow the progression of early Alzheimer's disease. It involved 856 people with either mild cognitive impairment or mild dementia due to Alzheimer's. Participants received different doses of the dru…
Phase: PHASE2 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New combo therapy shows promise against Tough-to-Treat uterine cancer
Disease control CompletedThis large, completed Phase 3 trial tested whether a new combination of two drugs (lenvatinib and pembrolizumab) worked better than standard chemotherapy for women with advanced endometrial cancer that had worsened after initial treatment. The main goal was to see if the combinat…
Phase: PHASE3 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
New combo therapy tested for Tough-to-Treat cancers
Disease control CompletedThis study tested the safety and effectiveness of a new drug, E7386, combined with an existing immunotherapy (pembrolizumab) for people with advanced melanoma, liver cancer, or colorectal cancer that had worsened after prior treatments. The first part checked for side effects and…
Phase: PHASE1, PHASE2 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Mar 17, 2026 13:10 UTC